121 related articles for article (PubMed ID: 38307556)
21. Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer.
Kato H; Furuya Y; Miyazawa Y; Miyao T; Syuto T; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2016 Nov; 36(11):6141-6149. PubMed ID: 27793943
[TBL] [Abstract][Full Text] [Related]
22. Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer.
Yashi M; Nishihara D; Yokoyama M; Fuchizawa H; Okazaki A; Takei K; Suzuki I; Sakamoto K; Kijima T; Kobayashi M; Kamai T
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1762. PubMed ID: 36470854
[TBL] [Abstract][Full Text] [Related]
23. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
24. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
25. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.
Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V
Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281
[TBL] [Abstract][Full Text] [Related]
26. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
Efstathiou E; Titus M; Wen S; Hoang A; Karlou M; Ashe R; Tu SM; Aparicio A; Troncoso P; Mohler J; Logothetis CJ
Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
[TBL] [Abstract][Full Text] [Related]
28. The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Liu RJ; Hu Q; Li SY; Mao WP; Xu B; Chen M
Technol Cancer Res Treat; 2021; 20():15330338211035260. PubMed ID: 34313171
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer.
Shiota M; Kobayashi T; Kashiwagi E; Takeuchi A; Inokuchi J; Tatsugami K; Eto M
Urol Oncol; 2019 Nov; 37(11):813.e21-813.e26. PubMed ID: 31202731
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
31. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns.
De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J
Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
[TBL] [Abstract][Full Text] [Related]
34. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
35. Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.
Cursano MC; Conteduca V; Scarpi E; Gurioli G; Casadei C; Gargiulo S; Altavilla A; Lolli C; Vincenzi B; Tonini G; Santini D; De Giorgi U
Sci Rep; 2022 May; 12(1):7319. PubMed ID: 35513478
[TBL] [Abstract][Full Text] [Related]
36. The presence of lymph node metastases and time to castration resistance predict the therapeutic effect of enzalutamide for castration-resistant prostate cancer.
Oka T; Hatano K; Okuda Y; Yamamoto A; Uemura T; Yamamichi G; Tomiyama E; Ishizuya Y; Yamamoto Y; Kato T; Kawashima A; Fujita K; Nonomura N
Int J Clin Oncol; 2023 Mar; 28(3):427-435. PubMed ID: 36580184
[TBL] [Abstract][Full Text] [Related]
37. Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T; Mori K; Yasue K; Matsukawa A; Fukuokaya W; Yanagisawa T; Hata K; Murakami M; Koike Y; Miki J; Yamada H; Kimura T
Int J Clin Oncol; 2024 Feb; 29(2):213-221. PubMed ID: 38103156
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
39. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract][Full Text] [Related]
40. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
